转甲状腺素蛋白心脏淀粉样变性中锝-99m焦磷酸盐的非心脏摄取
该回顾性分析纳入57例确诊转甲状腺素蛋白心脏淀粉样变性(ATTR)患者,行锝-99m焦磷酸盐(TcPYP)显像,定性和定量评估骨骼肌摄取。结果显示骨骼肌摄取极少,且不与心肌或骨摄取程度相关,提示TcPYP非心脏摄取特性可能不同于TcDPD。
要点
- 57例ATTR患者行TcPYP显像,定性SPECT未见骨骼肌或软组织示踪剂摄取。
- 骨骼肌总摄取及血池校正摄取均显著低于心肌和骨(P < 0.001)。
- 血池校正骨骼肌摄取与半定量2级 vs 3级摄取及遗传性ATTR均无显著关联。
核心结论
- 在ATTR心脏淀粉样变性患者中,TcPYP的骨骼肌摄取经定性和定量评估均极少,且在半定量2级与3级摄取患者间无显著差异。
- TcPYP在非心脏摄取方面可能具有与TcDPD不同的特性。
研究设计与样本
- 回顾性分析纳入57例确诊ATTR并接受TcPYP闪烁显像的患者。
- 心脏摄取采用全身平面成像半定量分级(0至3级)及带CT衰减校正的SPECT评估,计算每体素心肌总计数(孵育3小时后)。
- 计算骨骼肌(腰大肌和肱二头肌)、椎体、左心室心肌和血池的平均计数。
主要发现
- 队列年龄78 ± 9岁,男性占77%,遗传性ATTR占30%。
- 定性SPECT评估未见骨骼肌或软组织示踪剂摄取。
- 肌肉群总摄取及血池校正摄取均显著低于心肌和骨(P < 0.001)。
- 血池校正肌肉摄取与半定量3级 vs 2级摄取无关联(腰大肌P = 0.66,肱二头肌P = 0.13),与遗传性ATTR存在也无关联(腰大肌P = 0.43,肱二头肌P = 0.69)。
- 随着骨摄取减少,骨骼肌摄取无相应增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Technetium-based bone scintigraphy is rapidly becoming the most common non-invasive imaging tool in the diagnosis of Transthyretin cardiac amyloidosis (ATTR). Skeletal muscle uptake has been described with technetium-99m-3,3-diphosphono-1,2-propanodicarboxylic acid (TcDPD), and may account for masking of bony uptake. We sought to investigate skeletal muscle uptake of technetium-99m-pyrophosphate (TcPYP) in patients with ATTR. METHODS AND RESULTS: This was a retrospective analysis of 57 patients diagnosed with ATTR who underwent TcPYP scintigraphy. Cardiac uptake was assessed on whole-body planar imaging using a semiquantitative scale (grades 0 to 3) and on single-photon emission computed tomography (SPECT) with CT attenuation correction using total myocardial counts per voxel after a 3-hour incubation. Skeletal muscle (psoas and biceps), vertebral body, LV myocardium, and blood pool mean counts were calculated. In the cohort (age 78 ± 9 years, 77% male, and 30% hereditary ATTR), there was no visualized tracer uptake in skeletal muscle or soft tissue on qualitative SPECT assessment. Total and blood pool-corrected uptake in the muscle groups were significantly less than myocardium and bone (P < 0.001). Blood pool-corrected muscle uptake was not associated with semiquantitative grade 3 vs 2 uptake (psoas P = 0.66, biceps P = 0.13) or presence of hereditary ATTR (psoas P = 0.43, biceps P = 0.69). As bony uptake decreased, there was no corresponding increase in skeletal muscle uptake. CONCLUSIONS: In patients with ATTR cardiac amyloidosis, skeletal muscle uptake of TcPYP is minimal when assessed by qualitative and quantitative metrics, and is not significantly different in patients with grade 2 vs 3 semiquantitative uptake. The properties of this tracer may be different than TcDPD with respect to non-cardiac uptake.
引用
- Sperry BW, Gonzalez MH, Brunken R, et al. Non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis. J Nucl Cardiol. 2018. PMID: 29344917. doi:10.1007/s12350-017-1166-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。